1. PROSENSA HOLDING B.V. FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING

    Posted on May 28, 20134:25 pm

    Leiden, the Netherlands—May 28, 2013—Prosensa Holding B.V., today announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for Read more »

  2. New Developments with Prosensa and Sarepta for Exon Skipping in Duchenne

    Posted on 3:04 pm

    On Monday, the Today Show ran a segment about Jenn McNary and her two sons that have Duchenne, a deadly muscle disease that attacks primarily young boys.  Jenn had been passionate and effective in communicating the urgency of getting drugs for Duchenne approved by the FDA.   Jenn’s older son and thousands of boys like him need to Read more »

  3. Summary of GSK – Drisapersen Webinar

    Posted on May 6, 20138:31 pm

    DRISAPERSEN UPDATE: results from a randomized, double blind, placebo-controlled Phase II clinical trial Webinar with GlaxoSmithKline took place on Monday 6th May 2013, 9:00 am PDT. The webinar was to inform and update the Duchenne community on the Phase II clinical trial results for GSK2402968 (drisapersen) (DMD study 114117). Drisapersen is a 2’-O-methyl-phosphothioate oligo designed Read more »